These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 22347464)

  • 21. Gene fusion detection in formalin-fixed paraffin-embedded benign fibrous histiocytomas using fluorescence in situ hybridization and RNA sequencing.
    Walther C; Hofvander J; Nilsson J; Magnusson L; Domanski HA; Gisselsson D; Tayebwa J; Doyle LA; Fletcher CD; Mertens F
    Lab Invest; 2015 Sep; 95(9):1071-6. PubMed ID: 26121314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performance of Oncomine Fusion Transcript kit for formalin-fixed, paraffin-embedded lung cancer specimens.
    Sakai K; Ohira T; Matsubayashi J; Yoneshige A; Ito A; Mitsudomi T; Nagao T; Iwamatsu E; Katayama J; Ikeda N; Nishio K
    Cancer Sci; 2019 Jun; 110(6):2044-2049. PubMed ID: 30972901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions.
    Suehara Y; Arcila M; Wang L; Hasanovic A; Ang D; Ito T; Kimura Y; Drilon A; Guha U; Rusch V; Kris MG; Zakowski MF; Rizvi N; Khanin R; Ladanyi M
    Clin Cancer Res; 2012 Dec; 18(24):6599-608. PubMed ID: 23052255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
    Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
    J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Standard protocol of ALK fusion gene assessment by fluorescent in situ hybridization in non-small cell lung cancer].
    Guo L; Zheng S; Xie YQ
    Zhonghua Bing Li Xue Za Zhi; 2013 Aug; 42(8):530-3. PubMed ID: 24246918
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The biology and treatment of EML4-ALK non-small cell lung cancer.
    Sasaki T; Rodig SJ; Chirieac LR; Jänne PA
    Eur J Cancer; 2010 Jul; 46(10):1773-80. PubMed ID: 20418096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
    Inamura K; Takeuchi K; Togashi Y; Nomura K; Ninomiya H; Okui M; Satoh Y; Okumura S; Nakagawa K; Soda M; Choi YL; Niki T; Mano H; Ishikawa Y
    J Thorac Oncol; 2008 Jan; 3(1):13-7. PubMed ID: 18166835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase (ALK) alterations in patients with non-small cell lung cancer.
    Dama E; Tillhon M; Bertalot G; de Santis F; Troglio F; Pessina S; Passaro A; Pece S; de Marinis F; Dell'Orto P; Viale G; Spaggiari L; Di Fiore PP; Bianchi F; Barberis M; Vecchi M
    Oncotarget; 2016 Jun; 7(24):37160-37176. PubMed ID: 27206799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls.
    Demidova I; Barinov A; Savelov N; Gagarin I; Grinevitch V; Stroiakovaski D; Popov M; Laktionov K; Gutorov S; Smolin A; Olshanskaya Y; Obukhova T
    Arch Pathol Lab Med; 2014 Jun; 138(6):794-802. PubMed ID: 24878018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma.
    Betz BL; Dixon CA; Weigelin HC; Knoepp SM; Roh MH
    Cancer Cytopathol; 2013 Sep; 121(9):489-99. PubMed ID: 23536384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.
    Takeuchi K; Choi YL; Togashi Y; Soda M; Hatano S; Inamura K; Takada S; Ueno T; Yamashita Y; Satoh Y; Okumura S; Nakagawa K; Ishikawa Y; Mano H
    Clin Cancer Res; 2009 May; 15(9):3143-9. PubMed ID: 19383809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification.
    Takeuchi K; Soda M; Togashi Y; Sugawara E; Hatano S; Asaka R; Okumura S; Nakagawa K; Mano H; Ishikawa Y
    Clin Cancer Res; 2011 May; 17(10):3341-8. PubMed ID: 21430068
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reliability Assurance of Detection of EML4-ALK Rearrangement in Non-Small Cell Lung Cancer: The Results of Proficiency Testing in China.
    Li Y; Zhang R; Peng R; Ding J; Han Y; Wang G; Zhang K; Lin G; Li J
    J Thorac Oncol; 2016 Jun; 11(6):924-9. PubMed ID: 26988569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.
    Martelli MP; Sozzi G; Hernandez L; Pettirossi V; Navarro A; Conte D; Gasparini P; Perrone F; Modena P; Pastorino U; Carbone A; Fabbri A; Sidoni A; Nakamura S; Gambacorta M; Fernández PL; Ramirez J; Chan JK; Grigioni WF; Campo E; Pileri SA; Falini B
    Am J Pathol; 2009 Feb; 174(2):661-70. PubMed ID: 19147828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.
    Velizheva NP; Rechsteiner MP; Valtcheva N; Freiberger SN; Wong CE; Vrugt B; Zhong Q; Wagner U; Moch H; Hillinger S; Schmitt-Opitz I; Soltermann A; Wild PJ; Tischler V
    Pathol Res Pract; 2018 Apr; 214(4):572-578. PubMed ID: 29580750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
    Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
    Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR/Cas9 Technology-Based Xenograft Tumors as Candidate Reference Materials for Multiple EML4-ALK Rearrangements Testing.
    Peng R; Zhang R; Lin G; Yang X; Li Z; Zhang K; Zhang J; Li J
    J Mol Diagn; 2017 Sep; 19(5):766-775. PubMed ID: 28732214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer.
    Lira ME; Kim TM; Huang D; Deng S; Koh Y; Jang B; Go H; Lee SH; Chung DH; Kim WH; Schoenmakers EF; Choi YL; Park K; Ahn JS; Sun JM; Ahn MJ; Kim DW; Mao M
    J Mol Diagn; 2013 Jan; 15(1):51-61. PubMed ID: 23246132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
    Noh KW; Lee MS; Lee SE; Song JY; Shin HT; Kim YJ; Oh DY; Jung K; Sung M; Kim M; An S; Han J; Shim YM; Zo JI; Kim J; Park WY; Lee SH; Choi YL
    J Pathol; 2017 Nov; 243(3):307-319. PubMed ID: 28741662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel fusion of TPR and ALK in lung adenocarcinoma.
    Choi YL; Lira ME; Hong M; Kim RN; Choi SJ; Song JY; Pandy K; Mann DL; Stahl JA; Peckham HE; Zheng Z; Han J; Mao M; Kim J
    J Thorac Oncol; 2014 Apr; 9(4):563-6. PubMed ID: 24736082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.